What is Taconic?
Founded in 1952 and headquartered in Rensselaer, New York, Taconic Biosciences operates as a fully-licensed provider of animal solutions for the research community. The company facilitates the acquisition, custom generation, breeding, preconditioning, testing, and distribution of valuable research models globally. Taconic's comprehensive services support a wide array of scientific endeavors, enabling advancements in various fields of study.
How much funding has Taconic raised?
Taconic has raised a total of $142M across 2 funding rounds:
Debt
$2M
Debt
$140M
Debt (2020): $2M with participation from PPP
Debt (2022): $140M led by MidCap Financial
Key Investors in Taconic
MidCap Financial
MidCap Financial is a debt financing provider known for its flexible and efficient solutions, aiming to support companies with timely capital to drive their growth initiatives.
PPP
Public-Private Partnership
What's next for Taconic?
The recent major strategic investment, coupled with substantial prior debt financing, positions Taconic for continued expansion and innovation in the genetically engineered rodent model market. This capital will likely fuel further development of advanced animal models, enhance operational capabilities, and support the company's global distribution network. Taconic's long history and established infrastructure suggest a focus on scaling its enterprise-level solutions to meet the growing demands of pharmaceutical and biotechnology research.
See full Taconic company page
